On July 21, 2026 Propanc Biopharma, Inc. (Nasdaq: PPCB) ("Propanc" or the "Company"), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, reported that the Company and its joint research partners at the Universities of Jaén and Granada published key findings in a peer reviewed journal, Microbial Cell Factories, regarding the evaluation of recombinant trypsinogen and chymotrypsinogen for improving production for applications in biotechnology research. Specifically, human therapeutic use intended for the treatment of a range of chronic diseases including cancer and fibrosis. The Microbial Cell Factories journal is a leading peer-reviewed journal that focuses on applied microbiology. The publication, entitled, "Evaluation of recombinant trypsinogen and chymotrypsinogen production in Komagataella phaffii through co-expression of HAC1 and PDI1," is available online.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Funded and coordinated by Propanc in collaboration with the Company’s joint research partners, the program is designed to produce a backup, clinical compound to the Company’s lead product candidate, PRP, from bovine sources, initially targeting metastatic cancer from solid tumors. According to Emergen Research, the global metastatic cancer market is projected to be worth over $111 Billion by 2027. Key findings from the research conducted by Dr. Aitor González determined that it is possible to scale up production of both proenzymes trypsinogen and chymotrypsinogen using recombinant technology resulting in stable purified proteins.
The recombinant proenzyme product candidate, designated rec-PRP, will be produced at small scale quantities under non-GMP (Good Manufacturing Practice) conditions to establish compatibility with the naturally derived, bovine sourced product before determining the regulatory pathway for entering the clinic. Rec-PRP is a follow-on product to the Company’s lead asset, PRP, which is targeting a Phase 1b First-In-Human clinical study in advanced cancer patients suffering from solid tumors early 2027.
"A fully synthetic recombinant version of PRP is the next phase of our strategic plan in building a new therapeutic drug class aimed at treating a range of chronic diseases that remain a high unmet medical need and life threatening for many patients, but not at the expense of severe toxicity often associated with standard treatment options," said Mr. James Nathanielsz, Propanc’s Chief Executive Officer. "Our novel technology uses proteolytic action (breakdown of proteins) to enforce malignant cells to return to a natural state that restores cellular function and so they die off naturally, which induces anti-cancer and anti-tumor effects by altering the micro-immune environment. Our vision is to produce both products as cost-effective and practical solutions that can be administered globally. We are pleased with our progress as the Company enters a transformative stage with its R&D programs."
Rec-PRP could have additional benefits to the global healthcare system that could further capitalize on a new therapeutic approach to chronic diseases such as cancer and fibrosis. For example, both proenzymes are synthesized by an in vivo (living organism) system to produce crystallized proteins that could be maintained for long periods without suffering degradation in the absence of refrigeration. This will be useful for a longer shelf life as well as global distribution of the product, particularly in warmer climates and developing regions where refrigeration may not be available.
(Press release, Propanc, JUL 21, 2026, View Source [SID1234669341])